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Abstract: Nucleic acid aptamers hold promise as therapeutic tools for specific, tailored inhibition of
protein targets with several advantages when compared to small molecules or antibodies. Nuclear
WW domain containing E3 ubiquitin ligase 1 (WWP1) ubiquitin ligase poly-ubiquitinates Runt-related
transcription factor 2 (Runx2), a key transcription factor associated with osteoblast differentiation.
Since WWP1 and an adapter known as Schnurri-3 are negative regulators of osteoblast function, the
disruption of this complex has the potential to increase bone deposition for osteoporosis therapy.
Here, we develop new DNA aptamers that bind and inhibit WWP1 then investigate efficacy in an
osteoblastic cell culture. DNA aptamers were selected against three different truncations of the
HECT domain of WWP1. Aptamers which bind specifically to a C-lobe HECT domain truncation
were observed to enrich during the selection procedure. One particular DNA aptamer termed C3A
was further evaluated for its ability to bind WWP1 and inhibit its ubiquitination activity. C3A
showed a low µM binding affinity to WWP1 and was observed to be a non-competitive inhibitor of
WWP1 HECT ubiquitin ligase activity. When SaOS-2 osteoblastic cells were treated with C3A, partial
localization to the nucleus was observed. The C3A aptamer was also demonstrated to specifically
promote extracellular mineralization in cell culture experiments. The C3A aptamer has potential
for further development as a novel osteoporosis therapeutic strategy. Our results demonstrate that
aptamer-mediated inhibition of protein ubiquitination can be a novel therapeutic strategy.
Keywords: aptamer; SELEX; ubiquitin ligase; WWP1; targeted drug delivery
1. Introduction
In mammalian bone, the osteoblast is exclusively responsible for the deposition of bone matrix
in the form of hydroxyapatite crystals together with various structural proteins [1]. The osteoblast
lineage is largely controlled by Runx2 (Runt–related transcription factor 2/CBFA1/PEBP2αA), often
considered the “master regulator” of osteoblast differentiation [2]. The importance of Runx2 is
illustrated by observations that Runx2 null mice cannot produce mineralized bone due to a lack of
early stage osteoblasts [3]. The Nedd4 family HECT (‘Homologous to the E6-AP Carboxyl Terminus’)
domain E3 ligase WWP1, in complex with an adapter Schnurri-3 (Shn3), ubiquitinates Runx2 thus
leading to its degradation and reduction of osteoblast-mediated bone matrix synthesis [2]. WWP1 and
Shn3 proteins negatively regulate Runx2 at the protein level, hence are promising targets to stimulate
osteoblast differentiation, and by extension, higher bone mass in osteoporosis patients [4,5]. Human
WWP1 was discovered in 1997 and contains an independently active HECT domain (Homologous
to the E6-AP carboxyl terminus) which has its crystal structure solved [6–8]. WWP1 is structurally
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and functionally characterized, is readily “expressible” in E. coli, and inhibition of WWP1 to maintain
Runx2 levels is a promising therapeutic strategy to stimulate osteoblast function.
Nucleic acid aptamers are short, single-stranded nucleic acid chains evolved to bind specifically
to a given target. Riboswitches can be considered as natural non-coding RNA aptamers which regulate
gene expression upon binding a metabolic target [9]. Since 1990, aptamers have been created in the
laboratory using a process known as Systematic Evolution of Ligands by Exponential Enrichment
(SELEX) [10,11]. First, a large pool of random sequences (~1015) is exposed to a target, washed
to exclude non-binding species, and eluted to recover binding species. Second, the pool is PCR
amplified by having included 3’ and 5’ primer binding regions. Finally, the sequences are enriched
by repeating the process successively while introducing increased stringency (i.e., more rigorous
washing conditions and counter-selections of related targets). The SELEX iterations are continued
until enriched pools of homologous sequences are revealed, which then hold the potential to be tightly
binding and specific [10,11]. Aptamers often bind to their targets with KD values in the µM to nM
range with aptamer affinity maturation developed to increase affinity and specificity [12]. Aptamers
have secondary structure including hairpins, loops, pseudoknots, triplexes, and quadruplexes [13–15].
SELEX can be applied to a wide variety of targets ranging from small molecules to cells [16,17].
Due to these complexities and features, aptamers are sometimes compared and contrasted with both
antibodies and small molecules for use as therapeutics [18,19], diagnostics [20–22], and laboratory
tools [23]. Importantly, recent work has demonstrated methods that lower the cost of single stranded
oligonucleotide synthesis by several orders of magnitude [24].
Aptamers have traditionally focused on extracellular targets. However, polynucleotides such as
aptamers can enter the intracellular space by either: (1) extraneous means such as liposomes, polymers,
viruses, microinjection, electroporation, particle bombardment, calcium phosphate precipitation and
ultrasound, or by (2) inherent mechanisms such as endocytosis or pinocytosis [25–28]. Using cationic
reagents, aptamers can be transfected as is commonly practiced with plasmids. Naked DNA, without
the company of reagents, does enter the cell to some degree in spite of electrostatic repulsion, as was
demonstrated when internalized plasmids were found to express proteins [29]. Uptake depends both
on temperature and oligonucleotide length [30]. It has also been found that two putative cell surface
receptors are specific to oligonucleotides generally [31]. More recently, aptamers have been conjugated
to moieties to bind an internalizing receptor, or may be selected to bind the internalizing receptor
themselves [26,32]. Approximately 19,000 DNA molecules can be internalized by one cell once cationic
lipoplexes have fused with the anionic plasma membrane [33]. Aptamers can also be transcribed
directly in the cell, this type of aptamer has been coined an “intramer” [34–36].
Previously, our group selected aptamers which bind and inhibit the activity of the extracellular
protein sclerostin, which is a known negative regulator of bone formation [19]. Here, we investigate
an alternative intracellular strategy where the intracellular protein WWP1 is targeted with a DNA
aptamer. Herein we select and characterize DNA aptamers against the HECT domain of WWP1.
We investigate aptamer binding to its target, specific inhibition of its function, observe localization,
and evaluate efficacy in SaOS-2 osteoblastic cells.
2. Results
2.1. Strategy to Select DNA Aptamers against HECT Domain of WWP1
As it is not possible to express the full length WWP1 protein in E. coli, truncations of the smaller
yet active HECT domain were used as the targets for aptamer selection. The HECT domain has two
lobes: the N-lobe is involved in E2 binding and the C-lobe is important in ubiquitination [8]. Rotation
around a hinge between the two lobes is critical to WWP1 ubiquitin ligation activity [8], hence the
HECT domain is central to WWP1 function.
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As shown in Figure 1A, we expressed and purified three WWP1 truncations for use as targets in
our aptamer selections: the entire HECT domain, the N-lobe of the HECT domain and the C-lobe of
the HECT domain.
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Figure 1. Structure of W P1 HECT domain target and selected pool. (A) WWP1 HECT structure as
generated by pyMOL with functionally important regions labeled; (B) Variable regions of the enriched
pool for C-lobe with the three most abundant groups of identical sequences are boxed (C1–C3 where
B indicates without constant regions), and phylogenetic tree of sequenced aptamers showing inter
familial relationships.
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To begin, we used the entire HECT domain for the first 8 rounds of DNA aptamer selection.
Important to its inhibition, HECT domain requires a flexible hinge loop, the binding of an E2 adapter,
and a catalytic cysteine residue for activity (Figure 1A). We then proceeded to lobe-specific selections
to target particular functional regions more specifically. To further increase specificity as well as
stringency, C-lobe selections included N-lobe counter selections, N-lobe selections included C-lobe
counter selections, and HECT selections included ubiquitin as a general protein counter selection.
During the sequencing of pools throughout the process, the C-lobe pools proved to enrich promisingly,
while HECT and N-lobe selections did not enrich. This indicated that DNA aptamers had been selected
in the initial rounds that likely bind to the C-lobe of the HECT domain.
We performed 4 further SELEX lobe-specific rounds (after the 8 round HECT domain
pre-enrichment). Cloning and sequencing identified 31 aptamer sequences against the C-lobe
truncation (Figure 1B), annotated as C#A when constant region is included and C#B without. The
relationships between the variable regions is somewhat scattered—C3 is more closely related to C1
while C2 is completely unrelated. These three sequences were chosen to move forward in the project
due to their higher copy number in sequencing data.
To compare the predicted secondary structures of the three aptamers, mFold software (version 2.3,
The RNA Institute, State University of New York at Albany, Albany, NY, USA) was used (Figure 2).
The structure of the variable region mirrors that of its full-length counterpart for aptamer C1, but
not for C2 and C3; possibly indicating that full length is required for C2 and C3 binding (Figure 2).
Experiments were therefore carried out subsequently with constant regions included (indicated by the
A suffix).
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2.2. Determination of Binding Affinity of DNA Aptamers Binding to HECT Domain
We next investigated the relative affinity of the DNA aptamers for the protein target relative
to control. To demonstrate qualitative binding of the C-lobe aptamers to our recombinant HECT,
Electrophoretic Mobility Shift Assay (EMSA) was employed (Figure 3). EMSA is a hallmark method for
characterization of protein-nucleic acid binding. However, EMSA has shortcomings such as complexes
differing in stability depending on the gel medium and secondary binding confusing the magnitude of
the binding of interest. Thus, we view EMSA here as a relative and semi-quantitative characterization
of binding. The full-length aptamers C1A–C3A (the A indicating inclusion of the constant flanking
region) were incubated with a range of HECT concentrations then analyzed by PAGE electrophoresis
(Figure 3A), and the resultant band intensities were plotted (Figure 3B). Aptamer bound to protein
remains at the top of the gel, while free aptamer migrates normally. Of the three C-lobe aptamers,
C3A showed the strongest binding affinity. We observed that C3A shows a multimeric band above
its monomer band also, which may imply a multimer in equilibrium with the monomer (74 bp).
A KD roughly in the low µM range was estimated for aptamer C3A, while other C-lobe aptamers
and controls did not produce an inflection point with which to base a determination but with clearly
weaker binding. Therefore, in later experiments we focused on aptamer C3A as the most promising of
the three aptamer candidates.
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Figure 3. Determination of KD for aptamers using electrophoretic mobility shift assay (EMSA) for
aptamers C1A, C2A, and C3A. (A) 10% PAGE gels showing bound (upper bands) versus unbound
(lower bands) aptamer; (B) Plot of HECT concentration versus normalized band intensity (unbound)
with a one-site binding fit from representative data in Figure 3A.
2.3. Determination of C-Lobe DNA Aptamer-Mediated Inhibition of Ubiquitination Activity of HECT Domain
The HECT domain’s abilit t self- biquitinate with the requirement of an E1 and E2 protein
in it provides an approach to obs rv th kinetics of HECT domain activity. When the HECT
domain is ubiquitinated, the HECT domain-ubiquitin conjugate is o served by SDS-PAGE app aring
several kilodaltons above HECT and can be used for quant tation (Figure 4C). We u ed this ass y to
generate Michaelis-Menten curves between aptamers 1 –C3A which mplicates aptamer C3A as the
strongest inhibitor of the three (Figure 4A).
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Figure 4. Aptamer mediated inhibition of HECT ubiquitination. (A) Rate of reaction product
formation plotted against ubiquitin concentration (Michaelis-Menten) for aptamers C1A–C3A to
compare inhibition rates between aptamers from representative gel data. (B) Resultant Vmax and KM
values from the Michaelis-Menten plot. (C) 12% SDS-PAGE gel showing the reaction product over
increasing C3A concentrations; (D) Logarithmic plot of C3A aptamer concentration to band intensity
as measured to determine IC50 from representative gel data (E) Michaelis-Menten plot of two different
C3A concentrations for determination of mode of inhibition from representative gel data. (F) Summary
of Vmax and KM values tabulated for the two C3A concentrations.
The resulting vmax and KM are tabulated in Figure 4B and reconfir s aptamer C3A as the strongest
inhibitor. This result is also consistent with our observations of aptamer binding in Figure 3. Figure 4C
shows the ubiquitination assay on an example gel over a series of aptamer C3A concentrations, where
substrate and reaction product are labeled (residual ubiquitin (~10 kD) and E2 (~10 kD) can also be
seen). The plot of C3A concentration to band intensity of reaction product (Figure 4D) determines an
IC50 of approximately 100 µM. To determine mode of inhibition, two different C3A concentrations
were tested (100 µM and 200 µM) while varying the concentration of ubiquitin substrate to determine
KM and vmax as shown in Figure 4E,F. The presence of the inhibitor caused a significant reduction in
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the apparent vmax while the apparent KM remained similar. These results imply that the aptamer acts
as a non-competitive inhibitor of ubiquitination.
2.4. Cellular Localization, Runx2 Levels, and Bone Mineralization in Saos-2 Osteoblastic Cells
Fixed and stained SaOS-2 cells were imaged after the transfection process to investigate differences
in localization. These stained images were used to compare aptamer C3A and control, both with and
without transfection reagent as shown in Figure 5A. Although the images are overexposed, we were
able to gain information about the relative abundance of aptamer in the cytoplasm versus nucleus.
In this representative example, aptamer C3A without transfection (CN) appears to enter the cell, but
appears mostly proximal to the nucleus, whereas aptamer C3A with transfection (CT) seems to localize
both in the nucleus and cytosol.
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Figure 5. Aptamer C3A localization, and effect on Runx2 levels and bone mineralization in SaOS-2
cells. (A) Aptamer (Cy3) nucleus (Hoechst) overlays where: RN—random sequence control without
transfection, RT—random sequence control with transfection, CN—aptamer C3A without transfection,
and CT—aptamer C3A with transfection; (B) Aptamer and nucleus overlays over time points in hours;
(C) Quantitative assessment of nuclear localization using MetaMorph™ software for transfected or
naked (labeled as “NEAT”) aptamer C3A and random sequence control; (D) Western Blot of Runx2
performed on SaOS-2 cell extracts; (E) Quantitation of extracellular matrix deposition over time using
Alizarin Red assay.
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After determining that aptamer enters the cells without transfection reagent, we compared
localization over time by incubating aptamer C3Awith SaOS-2 cells without transfection reagent over
5 time points (Figure 5B). All aptamer samples appear to enter the cell and the images depict migration
towards the nucleus over time. Percent nuclear localization over time was quantified by image intensity
where hundreds of cells were batch processed using MetaMorph™ software (64-bit version, Molecular
Devices Corp., Sunnyvale, CA, USA) for aptamer C3A and control, with and without transfection
(Figure 5C). Whether or not transfection reagent was used, aptamers appear to enter the cell and
localize partially in both the cytoplasm and nucleus to some degree. There are examples where all
aptamers are exclusively in the cytoplasm for a period of time, but these results show that for most
cells, a proportion (>50%) of the aptamers end up in the nucleus quickly after exposure. To see if
treatment with aptamer C3A had an effect on Runx2 protein expression levels in SaOS-2 cell extracts, a
western blot was performed (Figure 5D). Data were consistent with a slight reduction of Runx2 levels
when cells were transfected with C3A relative to controls (Figure 5D). To determine if aptamer C3A
influenced osteoblast ability to deposit extracellular matrix, SaOS-2 cells were subjected to an Alizarin
Red assay to quantify calcific deposition (Figure 5E). At a timepoint 15 days after transfection it was
clear that both the naked C3A aptamer and the transfected C3A aptamer were able to increase the rate
of calcific deposition of the cells relative to control aptamers (Figure 5E). This data would be consistent
with an observation that the C3A aptamer is able to enter the cell even in the absence of the transfection
reagent and increase calcific extracellular matrix deposition. We also investigated the influence of
aptamer C3A on apoptosis and observed that aptamer C3A promoted apoptosis significantly more
than a random sequence control (Figure S1).
3. Discussion
Aptamer selections were begun with an entire HECT domain ‘pre-selection’. Subsequent
selections against N-lobe, C-lobe and HECT pool showed enrichment of Aptamers only against
C-lobe. This indicated that the C-lobe likely had selected tight-binding aptamers early in the selection
process. We observed that it was necessary to retain the flanking constant regions in the C-lobe
aptamers. Two classic examples of aptamers for which the PCR constant regions were not necessary for
binding are pegaptanib and the anti-thrombin aptamer, but others have been reported where constant
regions were required for binding [37,38]. We surmise that the necessity of flanking regions in an
aptamer varies from selection to selection.
Concerning our WWP1 truncation targets themselves (Figure 1), some structural features are
relevant. First, the C-lobe portion of the related E3 ubiquitin ligase UbR5 has its crystal structure solved
and was found to be active [39]. Nevertheless, we assumed our C-lobe truncation was unlikely to have
activity considering previous reports had shown that the N-lobe is necessary for the ubiquitination
reaction [8]. Our best C-lobe targeting aptamer C3A, which had been pre-selected against HECT
domain, was shown to specifically bind HECT (Figure 3). This implies that the C-lobe truncation most
likely folded into a similar structure as that in the context of the whole protein, consistent with the
demonstrated activity of UbR5 [39]. Many ubiquitin ligases have been identified as disease targets.
This is the first attempt to inhibit HECT ubiquitin ligase activity with an aptamer and we therefore do
not have a direct comparison of binding affinity for this specific family of targets [40]. Aptamers often
bind to targets with nanomolar affinities, but the KD of our C3A could be estimated in the low µM
range. We were not able to obtain estimations from our other aptamers and control because they did
not bind sufficiently at the tested range of concentrations, but one may conclude their binding was far
weaker (Figure 3).
Ubiquitination assays to determine inhibition are well-established [41]. HECT ligases in particular
are commonly studied from many angles with such assays [41]. Other groups have detected
ubiquitination by anti-ubiquitin western blotting, but we found this step unnecessary given the
quantitative Coomassie stain from the reaction product on the gel, which we confirmed to be ubiquitin
conjugated HECT with mass spectrometry [40]. Nevertheless, IC50 values for aptamers are rarely
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reported because enzymes are typically targeted by small molecules. There are some examples,
however, such as G-quadruplex aptamers against Shp2 phosphatase which inhibited Shp2 activity at
29 nM, while small molecules inhibited in the µM range [42]. Conversely, anti-sclerostin antibodies
inhibit in the nM range, while aptamers for the same protein inhibit at 15 µM [19,43]. Evidence of the
mode of inhibition could be seen with our Michaelis-Menten curves and apparent vmax and KM values,
which were consistent with non-competitive inhibition. Overall these pieces of evidence support
the possibility that aptamer C3A binds specifically to HECT domain and inhibits its activity in a
non-competitive manner (Figures 3 and 4).
There are 3 known mechanisms for DNA to enter a eukaryotic cell without transfection or a virus:
pinocytosis, absorptive endocytosis, or receptor mediated endocytosis [31,44]. In our assessment of
aptamer C3A localization in SaOS-2 cells, we found qualitatively that the aptamer appeared to be
able to enter the cell in the presence of absence of transfection reagent (Figure 5A). Here, we can only
assume that the DNA in the non-transfected samples entered by the abovementioned mechanisms.
Recently, aptamers for the intracellular and membrane target nucleolin were demonstrated to enter
via macropinocytosis [45]. In addition, non-specific DNA internalizing receptors exist in other cell
types but are not known in osteoblasts [27,28]. Both transfected and non-transfected samples were
treated with DNA for 5 h, a time frame where aptamers could conceivably diffuse passively through
the nuclear pore complex (Figure 5B), which could be compared to eukaryotic cells expressing proteins
from plasmids which must enter the nucleus to be transcribed [29,46]. The percentage of signal
appearing in the nucleus region for the hundreds of cells we analyzed with batch processing averaged
around 60% (Figure 5C). One possible reason for this could be positively charged nuclear proteins
such as histones, trapping a certain proportion of the aptamers.
Regarding aptamer C3A effect on phenotype, Western blot results were not clear-cut but were
consistent with a slight reduction in Runx2 levels relative to controls (Figure 5D). The extracellular
matrix deposition assay was performed under the same treatment conditions as the localization
experiments and increased extracellular matrix was observed in the C3A treated cells relative to
controls for both transfected and non-transfected cells.
Overall these experiments show that a DNA aptamer can bind specifically to WWP1 C-lobe and
inhibit its target. Observations were consistent with the DNA aptamer entering the SaOS-2 cell nucleus,
inhibiting WWP1 ubiquitination of Runx2 then increasing extracellular matrix deposition. WWP1
has also recently been implicated as an oncogene indicating that further work on WWP1 inhibition is
warranted [47]. Finally, a recent paper demonstrated that interference of WWP1 led to the induction of
apoptosis in osteosarcoma cells [47], which is also consistent with apoptosis experiments which we
performed at the characterization stage (Figure S1). Further cell-based and animal-based experiments
will be required to better understand the applicability of the aptamer to promote bone mineralization.
4. Materials and Methods
4.1. HECT, C-Lobe, N-Lobe and E2 Cloning, Expression and Purification
HECT, C-lobe and N-lobe were amplified per Platinum® Pfx Polymerase (Invitrogen, Waltham,
MA, USA) guidelines from a human liver cDNA library. The following sequences were those for
which the expression inserts were designed: HECT Domain (bp 1916–3047 NCBI Reference Sequence:
NM_007013.3), C-lobe (bp 2687–3047 NCBI Reference Sequence: NM_007013.3), N-lobe (bp 2342–2587
in NCBI Reference Sequence: NM_007013.3). The resulting sequences, once inserted into pET28a(+)
(Novagen, Madison, WI, USA) vector, gave an N-terminal hexahistidine tags. Subcloning was initiated
by 1% agarose gel purification of the PCR product with Platinum® Pfx Polymerase (Invitrogen) of
each insert (approx 20 cycles) using QIAquick® gel extraction kit (Qiagen, Hilden, Germany). Inserts
were then digested with EcoRI and NdeI (New England Biolabs, Ipswich, MA, USA), 1% agarose gel
purified and extracted, and the concentration of the insert and vector was then determined using
absorbance at OD260/280 nm. Approximately 20 ng of insert and 10 ng of vector were put into
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ligation reaction with 1 µL ligase in total of 10 µL per instructions of T4 DNA ligase (New England
Biolabs). A frozen eppendorf of XL-1 Blue E. coli (Stratagene, San Diego, CA, USA) provided in house
was made competent and transformed by roughly following the pET System manual (Novagen).
Colonies were selected on 50 µg/mL kanamycin agar plates, grown in 1 mL cultures for exponential
growth phase, DNA was purified by QIAprep (Qiagen), and sequenced by Tech Dragon Limited™,
Hong Kong, China.
The pET28a(+) (Novagen) vectors containing in-frame and un-mutated insert for all three
truncations of HECT and pET-15b (Novagen) containing UbE2D2 (Addgene, Cambridge, MA, USA)
were transformed into E. coli BL21(DE3) using the vendor transformation protocol (Novagen®).
Overnight starter cultures of 30 µg/mL kanamycin containing LB media seeded 2–3 L cultures of the
same media. These large cultures were grown at 37 ◦C under shaking at 200 rpm for approximately
6 h at 37 ◦C and induced to express with 500 µM IPTG, and shaken at room temperature for 4–5 h
(C-lobe, N-lobe, and UbE2D2) and 4 ◦C overnight (HECT domain). Cell pellet was harvested by
centrifugation at 4000 rpm, for 25 min, at 4 ◦C. After careful decanting, cell pellet was stored at −20 ◦C
until purification. Column load was prepared by resuspending cell pellets in 20 mL of sonication
buffer (Tris/500 mM NaCl/20 mM imidazole/0.1% (v/v) TritonX (pH 7.4)) for every 500 mL of culture
and supplemented with Complete EDTA-free EASYpack protease inhibitor cocktail (Roche, Mannheim,
Germany) followed by sonication for 10 min on ice at 30% amplitude. Cell lysate was centrifuged at
13,000 rpm for 25 min at 4 ◦C. Supernatant was filtered and loaded onto His-trap HP Ni2+ affinity
column (GE Healthcare, Chicago, IL, USA) using a peristaltic pump. After loading, the column was
transferred to Vision™ Workstation (Applied Biosystems, Waltham, MA, USA). Real time UV trace
was analyzed with the accompanying Vision™ Software (SDS v. 2.3, Applied Biosystems, Foster City,
CA, USA). A gradient was run from 0% mobile phase A (50 mM Tris/500 mM NaCl/20 mM Imidazole
(pH 7.4))→ 100% mobile phase B (50 mM Tris/500 mM NaCl/500 mM Imidazole (pH 7.4)) over 20 min
at 3.5 mL/min and ~2 mL fractions were taken by hand throughout the gradient. Fractions were stored
at −20 ◦C. Overall, the proteins were of correct size, were derived from the correct sequence, had
purities of around 95% (excluding UbE2D2), and maintained a solubility of around 50% of the starting
fraction pool after one week at 4 ◦C. All proteins expressed in high yield (concentrations of 2–4 mg/mL)
and signal during imidazole gradients generally coincided with predicted isoelectric points.
4.2. SELEX Procedures
Basic methodologies and tools for aptamer selection were adapted from our labs previous
methods. A random DNA library was obtained from Tech Dragon Limited, Hong Kong containing
6.9 nanomoles of single stranded DNA of the following design: Aptamers→ 3’-CTAATACGACTC
ACTATAGG(N30)AAGCTTTGCAGAGAGGATCCTT-5’, Primers→ 3’-GATTATGCTGAGTGATATCC,
TTCGAAACGTCTCTCCTAGGAA-5’-Biotin. DNA was reconstituted in MilliQ H2O and contained a
total of 4.2 × 1015 DNA molecules of 1.15 × 1018 possible sequences from a variable region of N = 30.
Determination of the amount of protein target to be used was based on the Ni-NTA Agarose Beads
Handbook (Qiagen, Hilden, Germany) estimate that approximately 3 µg of protein bind to 10 µL
of bead solution. The amount of target protein necessary to saturate 10 µL of bead solution was
determined by exposing the beads to an increasing amount of protein, washing with selection buffer
(50 mM Tris/0.05% Tween-20/0→ 1.0 M NaCl (pH 7.3)), eluting with 1.0 M imidazole in selection
buffer, and visualizing on SDS-PAGE. After washing beads with protein buffer (50 mM Tris/400 mM
NaCl/0.05% Tween-20 (pH 7.3)), appropriate amounts of protein were added and beads, and washed
3 times again with protein buffer. A 25 µL aliquot of library was then diluted with 200 µL of selection
buffer and added to the beads, gently mixed, and set for 1 min. The beads were then washed with
1 mL of selection buffer 6–12 times depending on the round of selection. Protein bound to DNA
was eluted with 50 µL elution buffer (1.0 M imidazole in TBS, pH 7.5) and 5 µL was carried on to
PCR amplification with biotinylated reverse primer for ~10 cycles. The resulting double stranded
amplification product from each consecutive round was separated by washing 50 µL of Dynabeads
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M-280 Streptavidin magnetic beads (Invitrogen, Waltham, MA, USA) with 1 mL separation buffer
(50 mM Tris/0.05% Tween-20 (pH 7.3)), binding the entire 50 µL PCR product and 900 µL separation
buffer with the washed beads, washing three times with separation buffer, and eluting with 50 µL of
100 mM NaOH. DNA containing NaOH was diluted with 150 µL TBS for neutralization. Progression
of the selection process was monitored by PCR and PAGE. Pools of double stranded DNA from final
rounds of selections were blunt end cloned into vectors using Zero Blunt® TOPO® PCR Cloning Kit
(Invitrogen) and transfection of XL-1 Blue E. coli (Stratagene, San Diego, CA, USA) was performed as
previously mentioned. 50 colonies from 50 µg/mL kanamycin selective plates were grown in 2.5 mL
cultures for approximately 10 h, and said cultures were prepared for sequencing using the QIAprep®
Spin Miniprep Kit (Qiagen, Hilden, Germany). Sequencing of plasmids was performed by Tech Dragon
Limited, Hong Kong, China.
4.3. HECT Ubiquitin Ligase Activity Assay
A HECT ubiquitination assay was devised based on the general guidelines of the Boston Biochem®
Company which specializes in ubiquitin assays. Active HECT domain and the human E2 protein
(UbE2D2) were expressed in E. coli, purified as described previously and were kept at 100 ng/µL and
160 ng/µL, respectively, at −20 ◦C in ~25% glycerol. His6-tagged human recombinant Ubiquitin and
recombinant Human His6-Ubiquitin E1 Enzyme (UBE1) (Boston Biochem®) were kept at 5 µg/µL
and 250 ng/µL, respectively, at −20 ◦C. The reaction was optimized by starting at 250 ng E1, 300 ng,
HECT, 320 ng E2, and 5 µg Ub, and then systematically altering assay parameters such as reaction
volume, time, reagent amounts, and temperature. Finally, the reaction contained 2.6 µM HECT,
45.5 nM UBE1, 507.8 nM UBE2D2, and varying from 300 nM to 4.8 µM Ubiquitin depending on the
experiment. The total reaction volume was 25 µL, was run for 1 h at 37 ◦C in assay buffer (50 mM
Tris/50 mM NaCl/5 mM MgCl2/5 mM KCl/25 mM DTT/5 mM ATP (pH 7.5)), and stopped by
addition of 25 µL SDS-PAGE loading buffer (100 mM Tris/40% v/v glycerol/8% w/v SDS/5% w/v
beta-mercaptoethanol/0.04% w/v bromophenol blue (pH 7.5)) with a final gel load of 20 µL. Identity of
the reaction product band (HECT~Ub conjugate) was confirmed by MS/MS (Genome Research Center,
Hong Kong, China). Gels were stained with Coomassie or Silver depending on need for quantitation
and analyzed with ImageJ (NIH, Bethesda, MD, USA) and Prism® (version 7, GraphPad, San Diego,
CA, USA) softwares.
4.4. Electrophoretic Mobility Shift Assay (EMSA)
Briefly, 15 µL samples containing 11.3 µM→ 293.9 nM HECT domain, 55.6 nM aptamer, and
4 µL of EMSA sample buffer (50 mM Tris/10% (v/v) Glycerol/0.02% (w/v) bromophenol blue (pH 6.8))
were created. The mixture was set for 60 min at 4 ◦C while gel was pre-run in TAE buffer at 100 V
for equilibration. Samples were then loaded and run on 12% PAGE Gels which were prepared using
vendor Midi Protean Cell guidelines (BioRad, Hercules, CA, USA) at 100 V for approximately 3 h until
tracking dye reached bottom of the gel. Gels were stained with 3.5 µL of SYBR Gold Nucleic Acid
Gel Stain (Molecular Probes, Waltham, MA, USA) per 50 mL of TAE buffer and imaged in the UV
Transilluminator Imaging System (UVP, Hercules, CA, USA) and analyzed with ImageJ and Prism®.
6.5 pmol of aptamer was mixed with a series of concentrations of HECT, set for 1 h at 4 ◦C, run on 10%
PAGE for 1.5 h at 100 V in 4 ◦C with minimal glycerol for gel loading, and stained with SYBR gold™.
4.5. Cell Culturing
SaOS-2 Cells (ATCC® number HTB-85®), a human osteosarcoma line, were obtained in house
labeled at passage 5. Cells were thawed, seeded, passaged according to the general guidelines
of the Cell Culture Basics guide (Thermo Fisher Scientific, Hercules, CA, USA) in a Class II bio
safety cabinet with McCoy’s 5a Media (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
Penicillin/Streptomycin and 15% FBS, and centrifugation was performed on bench top centrifuge.
Cells were stored at a controlled environment of 37 ◦C with 5% CO2 and viewed with an Eclipse
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TS100 (Nikon, Tokyo, Japan) light microscope at 4× and 10× magnifications daily. Samples to be
prepared for fixed cell imaging, western blot, apoptosis, bone mineralization, and alkaline phosphatase
activity were initiated by growing cells to ~80% confluency on either 6, 24, or 96 well cell culture plates
(Corning Inc., Corning, NY, USA). Cells were transfected with 100 ng of aptamer and control for 4 h
per Lipofectamine 2000 (Invitrogen) guidelines using McCoy’s 5a Media (Sigma-Aldrich) without
Penicillin/Streptomycin or FBS or treated with aptamer and control without transfection reagent for
the same amount of time. Cells were then replaced with normal supplemented media after transfection,
which took place once (T0) for fixed cell imaging, western blot, and apoptosis assays and three times
(T0 then every 3 days) for mineralization and alkaline phosphatase assays. The cells remained alive for
the course of the experiments.
4.6. Fixed Cell Imaging
Cover slip containing Costar® 6 well flat bottom plates (Corning Inc., Corning, NY, USA) were
prepared with sterile technique by placing cover slips into the wells with forceps in the BSC hood,
rinsing with cold methanol, and rinsing 3× with ice cold sterile PBS. Cells were seeded 1:4 and grown
to ~90% confluency and then treated with aptamer and controls, with and without Lipofectamine™
2000. At each time point, wells were washed with ice cold PBS, gently fixed with ice cold methanol at
−20 ◦C for one hour and washed with ice cold PBS. After damping dry, Acrytol® mounting media
(Leica, Wetzlar, Germany) was used to mount slides, which were then dried overnight in the dark.
Images were taken on an BX51 Fluorescence Microscope (Olympus, Tokyo, Japan) using brightfield
and the appropriate filters for Cy3 (red) and Hoechst (blue) at 40×. MetaMorph® (Molecular Devices,
San Jose, CA, USA) batch processing software was used to analyze at least 85 cells per sample.
4.7. Runx2 Western Blot
Cells were first washed with ice cold PBS, then 200 µL of ice cold RIPA buffer (150 mM sodium
chloride/1.0% Triton X-100/0.5% sodium deoxycholate/0.1% SDS (sodium dodecyl sulfate)/50 mM
Tris (pH 8.0)) supplemented with complete EDTA-free EASYpack protease inhibitor cocktail was
added and cells, scraped and recovered by pipette. Lysates were agitated at 4 ◦C for 30 min by light
shaking and centrifuged for 20 min at 12,000 rpm on a X-15R bench top centrifuge (Beckman Coulter)
at 4 ◦C before recovering supernatant. In this case, Rabbit derived Anti-Runx2 (Novus Biologicals,
Littleton, CO, USA) and Goat derived Anti-Rabbit IgG (whole molecule) Peroxidase conjugate (Novus
Biologicals®) were used at 1/500 and 1/80,000, respectively, while generally following the Western
Blotting Beginners Guide (Abcam, Cambridge, UK). 1 µL of B-Actin (Cell Signaling Technology,
Danvers, MA, USA) stock was included with each primary antibody incubation as a loading control.
Blots were imaged with UV Transilluminator Imaging System (UVP, Hercules, CA, USA).
4.8. Apoptosis Assay
Apoptosis samples were prepared as described in the cell culture section and were performed
according to HT TiterTACS™ Assay kit (Trevigen, Gaithersburg, MD, USA) guidelines, read at 450 nm
on a 200 SpectraMax 340PC 38 (Molecular Devices) and analyzed with Soft Max Pro (Molecular
Devices) and Prism® (GraphPad) Software.
4.9. Bone Mineralization Assay
Assays to detect the calcium of bone deposition generally followed the Osteoblast Differentiation
and Mineralization Guide (PromoCell, Heidelberg, Germany). First, cells washed with ice cold PBS,
fixed with ice cold methanol overnight, stained with 20 g/mL Alizarin Red S for 45 min at room
temperature, washed 5 times with diH2O, and PBS added before digital photographs were taken.
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5. Conclusions
We successfully generated a DNA aptamer (C3A) which binds to the C-lobe of WWP1 with a
binding affinity of 1.9 µM. This aptamer was demonstrated to inhibit the ubiquitination activity of
WWP1 in a non-competitive manner. The aptamer could internalize into SaOS2 cells even in absence
of transfection agent. The aptamer was shown to stimulate extracellular matrix deposition relative to
controls. Future work can improve binding affinity by microarray maturation, employ bioinformatics
methods to modify the aptamer for greater functionality [48] or generate a library that could be used
alongside a microfluidic selection method [49]. By such approaches, novel therapeutic aptamers can
be further developed for a variety of human disease.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/3/763/s1.
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